Abstract The hereditary sensory and autonomic neuropathies (HSAN, also known as the hereditary sensory neuropathies) are a clinically and genetically heterogeneous group of disorders, characterised by a progressive sensory neuropathy often complicated by ulcers and amputations, with variable motor and autonomic involvement. To date, mutations in twelve genes have been identified as causing HSAN. To study the frequency of mutations in these genes and the associated phenotypes, we screened 140 index patients in our inherited neuropathy cohort with a clinical diagnosis of HSAN for mutations in the coding regions of SPTLC1, RAB7, WNK1/HSN2, FAM134B, NTRK1 (TRKA) and NGFB. We identified 25 index patients with mutations in six genes associated with HSAN (SPTLC1, RAB7, WNK1/HSN2, FAM134B, NTRK1 and NGFB); 20 of which appear to be pathogenic giving an overall mutation frequency of 14.3%. Mutations in the known genes for HSAN are rare suggesting that further HSAN genes are yet to be G. L. Davidson and S. M. Murphy contributed equally to the manuscript.
Introduction
The hereditary sensory and autonomic neuropathies (HSAN, also known as the hereditary sensory neuropathies, HSN) are a clinically and genetically heterogeneous group of disorders. The cardinal clinical feature is a predominantly sensory axonal neuropathy characterised by loss of sensation including pain and temperature and in some subtypes positive sensory symptoms such as pain and paraesthesiae. The sensory loss frequently results in complications such as ulcers, infections, osteomyelitis, selfmutilation and spontaneous or surgical amputations. Motor and autonomic involvement occur to a variable degree [8, 21] . HSAN has been traditionally classified into five groups (HSAN I-V) [2] based on mode of inheritance and clinical features. More recently the classification has included the known causative genes. To date, mutations in 12 genes have been identified as being responsible for HSAN (Table 1) .
Genetic analysis is essential in the diagnosis of patients with HSAN and has clarified the phenotypic spectrum and helped further the understanding of the mechanisms of sensory neuron degeneration. Rotthier et al. [24] investigated a cohort of 100 European patients with HSAN and found mutations in 19%; most frequently in RAB7 and NTRK1.
Mutations were also found in HSN2/WNK1 and SPTLC1; however, no mutations were present in CCT5 or NGFB.
This study was designed to determine if the frequency of mutations in the genes associated with HSAN is similar in our mainly UK cohort and to describe the associated phenotypes. A total of 140 index cases with HSAN/sensory predominant CMT2 were screened for mutations in the coding regions of SPTLC1, RAB7, WNK1/HSN2, FAM134B, NTRK1 and NGFB. We did not test for IKB-KAP or CCT5 as none of our patients had the distinctive phenotype of Riley-Day syndrome (HSAN III) and none had spastic paraplegia. We did not screen SPTLC2, ATL-1, DNMT1 or KIF1A as these recently described genes were reported subsequent to completion of this project.
Methods
This study was carried out in the National Hospital for Neurology and Neurosurgery (NHNN) and Institute of Neurology. Ethical approval was obtained from the joint medical and ethics committee at the NHNN. Written informed consent was obtained from all patients.
Patients
We selected a cohort of 140 patients from our inherited neuropathy database. These were patients presenting with a phenotype compatible with any of the forms of HSAN or CMT2 with a predominant sensory phenotype (Supplementary table) . Forty-one patients (29%) had definite autosomal dominant (AD) inheritance, 12 patients (9%) had presumed autosomal recessive (AR) inheritance and the remainder were either sporadic cases or the referring physician did not document inheritance. The database includes patients seen in the peripheral neuropathy clinics in the NHNN as well as patients' DNA referred from other hospitals for diagnostic and research testing. External referring physicians were neurologists with experience in neuromuscular disease. Sixty-seven patients (48%) included in this study were seen within our own department, the remainder were external DNA samples. When mutations were found in patients we had not seen personally, we either reviewed the patient or obtained detailed clinical information from the referring physician. Most patients presented with distal progressive sensory loss, with or without ulceromutilating complications or autonomic dysfunction. Because of the overlap between CMT2B and HSAN I we included patients who had motor involvement; however, sensory features were always predominant. Diagnosis was based on clinical phenotype in addition to neurophysiology.
DNA extraction, PCR and sequencing DNA was extracted from blood using Flexigene extraction kit and Autopure LS (Qiagen) extraction system. Coding regions and flanking introns were amplified using Roche or Qiagen PCR reagents. Primers and PCR conditions are available upon request. Reference sequences used were SPTLC1: NM_006415.2, RAB7: NM_0004637.5, HSN2/WNK1: NM_213655.1, FAM134B: NM_001034850.1, NGFB: NM_002506.2 and NTRK1 (TRKA): NM_002529.3.
Sequence reactions were performed using Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and resolved on an ABI 3730xl Sequencer. Sequence variants were confirmed by repeat sequencing. We considered variants pathogenic if they were absent from controls, segregated within families or, in the case of homozygous variants, if unaffected parents were heterozygous. We also considered conservation of amino acids among species and used three commonly used prediction programmes PolyPhen (http://genetics.bwh.harvard.edu/ pph/), SIFT (http://blocks.fhcrc.org/sift/SIFT.html) and aGVGD (http://agvgd.iarc.fr/). In addition, we checked the 1000genomes and NHLBI exome sequencing project databases (http://www.1000genomes.org and http://evs.gs. washington.edu/EVS) to determine whether novel variants had been reported previously. One hundred seventy chromosomes from British controls and 180 chromosomes from Asian controls were screened for all novel variants depending on ethnicity of the patient.
Results
We identified 25 patients with sequence variants in our cohort of 140 patients (17.9%), 20 of which (14.3%) are likely to be pathogenic. Mutations were found in all genes tested ( Table 2 ). Details on some of the patients with the RAB7, FAM134B and SPTLC1 mutations have been reported previously [9, 10, 18] . Patients with mutations varied in their clinical phenotype, although as expected there was more consistency in the phenotypes associated with individual genes ( Table 3 ). Pedigrees of the families are shown in Fig. 1 (families reported previously by us and newly diagnosed families with p.Cys133Trp SPTLC1 have not been included). All novel variants reported here were not detected in the control cohorts.
SPTLC1 mutations
We found mutations in SPTLC1 in 13 index patients with HSAN, all but one of which was the common p.Cys133Trp mutation. Seven of these families have been reported previously [9] . Patients presented in the second or third decades with decreased sensation in the feet; lancinating pain and paraesthesiae were common. Painless ulcers occurred in all families, with Charcot joints and amputations in some individuals, often with motor involvement. Neurophysiology demonstrated absent or reduced sensory action potentials (SAPs) with variable motor studies, usually demonstrating axonal loss but occasionally showing intermediate or demyelinating motor conduction velocities as we have previously described. There is insufficient evidence of pathogenicity for the novel variant p.Ala310Gly; this amino acid is only moderately conserved among species and two of three prediction programs suggested that this change would be tolerated (Table 4 ). This patient was adopted and is not available to investigate the pathogenicity of the mutation further with deoxysphingoid base (DSB) levels.
RAB7 mutations
We identified one family with a mutation in RAB7, p.Asn161Thr. This family has been described in detail previously [10] .
WNK1/HSN2 mutations
We identified two novel frameshift mutations in WNK1/ HSN2; a compound heterozygous mutation p.[Cys20Trpfs He had trophic ulcers on the fingers which were shortened due to repeated trauma. His parents were not consanguineous, he had an affected sister and cousin; DNA was not available from the other affected members of this family.
FAM134B mutations
We found a homozygous nonsense mutation in FAM134B (p.Gln145X), in a patient with HSAN II, which we and others have previously reported [13, 18] . A second variant, p.Gly216Arg, is most likely a rare polymorphism as the affected sibling did not carry the variant (Fig. 1, family 18 ).
NTRK1 mutations
Five variants were found within the NTRK1 coding region; all were homozygous and two are novel. Four of these are considered pathogenic.
One patient from Saudi Arabia (family 19, V.1), with consanguineous parents, had a homozygous nonsense mutation (p.Gln176X) [11] ; parents were heterozygous. Sural nerve biopsy demonstrated a reduction in small myelinated fibres and unmyelinated fibres, consistent with HSAN V [20] . In family 20, also from Saudi Arabia, there was a homozygous nonsense mutation (c.1069_1076dup-GGCAACTA) leading to a stop mutation, p.Tyr359X [17] in the proband; both his consanguineous, unaffected parents were heterozygous carriers. The third Saudi Arabian family, family 21, had a homozygous missense mutation (p.Arg654Cys) [17] . His parents were first cousins and unaffected, they as well as his unaffected sister were heterozygous (Fig. 1) .
The index patient from family 22 was found to have a novel apparently homozygous missense mutation, p.Glu492Lys. Born to an unrelated American mother and British father, this patient had a congenital sensory neuropathy with associated anhidrosis, seizures, deafness and developmental delay. Neurophysiology demonstrated a sensory neuropathy with additional involvement of the central sensory pathways. Family members were unavailable for segregation analysis; however, this amino acid is highly conserved across species and all prediction programs suggested that this amino acid change would be damaging (Table 4 ). This variant has been published on the http://evs.gs.washington.edu/EVS website as being present in eight of 7,020 European/American and three of 3,738 African/American alleles (i.e. 0.1% of chromosomes); thus this may represent a rare recessive pathogenic allele. PolyPhen2 uses alignments and (where possible) information on known functional protein domains to score variants from 0 (benign) to 1 (pathogenic)
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The variant p.Arg6Trp is unlikely to be relevant as the family have dominant inheritance and have subsequently been found to have a mutation in DNMT1 [12] . In addition, this variant has been reported to occur in 15/3,668 (0.4%) Europeans (http://evs.gs.washington.edu/EVS).
NGFB mutations
A heterozygous duplication, p.Gly161_Glu162dup, was found in a British female (Fig. 1, family 24) . This patient presented at 48 years with a progressive sensory axonal neuropathy with Charcot joints. There was a dominant family history of a similar neuropathy; however, all affected family members were deceased. Although we cannot prove that this duplication is pathogenic the phenotype is similar to the previously reported heterozgyous NGFB patients.
A second heterozygous variant (p.Ser187Asn) was found in a patient with CIP, family DNA was not available. We are unsure of the pathogenicity of this variant; we cannot rule out a non-coding mutation or deletion on the other allele.
Discussion
Our genetic screen of 140 patients with HSAN found 25 index patients with mutations in six genes (SPTLC1, RAB7, WNK1/HSN2, FAM134B, NTRK1 and NGFB), of which at least 20 are considered pathogenic; a frequency of 14.3%, similar to the 19% described by Rotthier et al. [24] . Our control groups were negative for all variations described, suggesting that none of these variants are common polymorphisms. None of the variants were reported on the 1000genomes database, although two of the NTRK1 variants were reported on the NHLBI database. We did not have enough evidence to support pathogenicity for five of the variants found (SPTLC1 p.Ala310Gly, FAM134B p.Gly216Arg, NTRK1 p.Arg6Trp and NGFB p.Gly161_-Glu162dup and p.Ser187Asn).
The purpose of this study was to determine the frequency of mutations in the genes known to cause HSAN in a mainly UK cohort. Mutations were most frequent in SPTLC1 (12%), found in British Caucasian patients with dominant inheritance and adult-onset disease. Mutations in NTRK1 were next most common (6%) and found predominantly in patients of Saudi Arabian descent with consanguineous parents. Mutations in all other genes were rare, accounting for \2% each. These results suggest that many more genes responsible for causing HSAN have yet to be identified. Since this study was completed, mutations in four further genes (ATL-1 [6] , SPTLC2 [23] , DNMT1 [12] and KIF1A [22] ) have been reported to cause HSAN; it is unknown whether mutations in these additional genes would contribute significantly more patients than that found in our cohort given the small number of patients reported to date.
When we analysed the number of cases with a genetic diagnosis based on inheritance pattern, we found causative mutations in 10/41 (24.4%) patients with AD inheritance and 5/12 (41.7%) patients with AR inheritance, versus 5/87 (5.7%) patients with unknown or sporadic inheritance; thus the likelihood of establishing a genetic diagnosis is higher in patients with a definite family history.
Mutations in SPTLC1 accounted for 12% of our patients with HSAN. All but one were the common p.Cys133Trp mutation, presenting with the typical HSAN I phenotype. We have previously demonstrated that this mutation occurs due to a founder effect in the UK [9] . Of the known disease-causing mutations in SPTLC1, all but two lie within exons 5 and 6, a region of the protein important for substrate specificity [19] . Altered substrate-specificity of the enzyme results in the formation and accumulation of toxic DSBs [3, 19] . Of the three reported mutations outside exons 5 and 6, p.Gly387Ala was subsequently demonstrated to be a polymorphism [7] . Our finding of mutations in SPTLC1 being the commonest cause of HSAN is in contrast to Rotthier et al. [24] who found mutations in RAB7 to be the most common in a European cohort. We only found one patient with a RAB7 mutation in our cohort [10] . This likely reflects the fact that in the European cohort, there was a founder effect for the p.Leu129Phe RAB7 mutation in Austrian patients [24] , while in the UK population there is a founder effect for the common p.Cys133Trp SPTLC1 mutation [9] .
Two patients with recessive mutations in HSN2/WNK1 were found. Both mutations cause a shift in the open reading frame, resulting in premature stop codons which likely render the protein non-functional. The phenotype of these patients was similar to previously reported patients with CIP [14] . Both of these mutations are novel but their absence in controls and segregation within both families supports pathogenicity.
The homozygous nonsense mutation in FAM134B, p.Gln145X [18] , was previously reported in a Turkish individual [13] . Both patients had onset in the first decade, with impaired nociception, ulcerations and amputations. Our patient did not have any autonomic dysfunction, and had significant motor involvement, in contrast to the patient previously reported.
Mutations in NTRK1 accounted for 6% of our HSAN cohort. The phenotype in the four families with pathogenic mutations was consistent with that reported in the literature with congenital insensitivity to pain with anhidrosis (CIPA), learning disability and sensory complications. Three of the mutations were heterozygous in unaffected parents/siblings and homozygous in affected individuals, supporting pathogenicity. p.Tyr359X, found in a Saudi Arabian patient with CIPA, was previously described in a Japanese patient [17] . It causes a frameshift, resulting in a premature stop codon which likely renders the protein nonfunctional. p.Arg654Cys, found in a consanguineous Saudi Arabian family, was homozygous in the affected individual while unaffected family members were heterozygous. This mutation was previously described by Miura et al. as p.Arg648Cys, using an alternative amino acid numbering system, who demonstrated that this amino acid is conserved among the three human TRK families, as well as among at least 14 other tyrosine kinase receptors [17] . The homozygous p.Gln176X NTRK1 mutation has been described previously in two patients from Kuwait with CIPA [11] . This nonsense mutation lies within the extracellular domain of the TRKA protein and would likely disrupt its function as a receptor for NGF [11] . Of the two novel variants, p.Glu492Lys is considered pathogenic. This was found in a patient with CIPA and cognitive delay; the amino acid is highly conserved across species and all three prediction programs suggested a damaging effect of the change, supporting pathogenicity.
We did not find any patients with homozygous mutations in NGFB, but found two patients with heterozygous variants. To date only one NGFB point mutation has been described in a family with HSAN V (p.Arg221Trp) [4, 16] , one family with HSAN IV was reported with a homozygous frameshift mutation due to a point mutation and two base pair deletion on the same allele (p.Val232fs) [1] and one patient with a sensory and autonomic neuropathy has been described with heterozygous deletion of 12 genes one of which was NGFB [5] . Although HSAN V is usually recessive, there is a suggestion that heterozygotes have a higher incidence of Charcot joints and neuropathy, as reported in a large family with p.Arg221Trp [15] . Our patient with a heterozygous duplication (p.Gly161_Glu162dup) has a similar phenotype; however, it is currently not possible to confirm whether this variant is pathogenic.
Mutations in the genes known to cause HSAN remain rare. Only 14.3% of this cohort of patients had a pathogenic mutation in a causative gene; thus there are clearly many more HSAN genes which remain unknown. Rapid advances in genetics have already led to the discovery of four additional HSAN genes since the completion of this study. The results of this study have allowed us develop an algorithm for genetic testing of patients with HSAN in the UK (Fig. 2) . Although the majority of the mutations found in our cohort are likely to be pathogenic, the exact mechanisms of how these mutations disrupt neural processes require further investigation. Functional studies may provide further understanding of these genetic effects giving insight into possible treatments.
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